BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models.
Rauh U, Wei G, Serrano-Wu M, Kosmidis G, Kaulfuss S, Siegel F, Thede K, McFarland J, Lemke CT, Werbeck N, Nowak-Reppel K, Pilari S, Menz S, Ocker M, Zhang W, Davis K, Poncet-Montange G, Roth J, Daniels D, Kaushik VK, Hubbard B, Ziegelbauer K, Golub TR.
Rauh U, et al. Among authors: kaushik vk.
Nat Cancer. 2024 Oct;5(10):1479-1493. doi: 10.1038/s43018-024-00814-0. Epub 2024 Aug 23.
Nat Cancer. 2024.
PMID: 39179926
Free PMC article.